“Bimekizumab Continuous Maintenance of Eesponse at Every Visit Through Two Years in Patients With Moderate to Severe Plaque Psoriasis: Post-Hoc Results from Five Phase 3 3b Trials”. SKIN The Journal of Cutaneous Medicine 8, no. 1 (January 16, 2024): s303. Accessed April 21, 2026. https://skin.dermsquared.com/skin/article/view/2436.